GLP-1 Receptor Agonists: Thyroid Cancer Contraindications
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2 (MEN-2). 1
Specific Contraindications
The FDA Black Box Warning applies specifically to:
- Medullary thyroid carcinoma (MTC) - personal history
- Medullary thyroid carcinoma (MTC) - family history
- Multiple endocrine neoplasia syndrome type 2A (MEN-2A)
- Multiple endocrine neoplasia syndrome type 2B (MEN-2B)
Important Distinctions by Agent
Not all GLP-1 receptor agonists carry the same contraindication profile:
- Longer-acting agents (semaglutide, liraglutide, exenatide ER, dulaglutide): Contraindicated in MTC and MEN-2 2, 3
- Shorter-acting agents (twice-daily exenatide, lixisenatide): These contraindications are not listed in their prescribing information 3
Differentiated Thyroid Cancer (DTC) - Not a Contraindication
GLP-1 receptor agonists are NOT contraindicated in differentiated thyroid cancer (papillary, follicular, or Hürthle cell carcinoma). 3
The evidence supporting this distinction:
The biological mechanism behind the rodent C-cell tumor findings does not apply to differentiated thyroid cancers, as human C-cells (which produce calcitonin and can develop into MTC) do not express GLP-1 receptors the way rodent C-cells do 3
Multiple meta-analyses have found no increased risk for thyroid cancer with GLP-1 receptor agonists or DPP-4 inhibitors in humans 3
Recent observational data from 536 patients with DTC exposed to GLP-1RA showed no significant association with disease recurrence or progression (HR 0.87,95% CI 0.62-1.21, P=0.39) 4
Patients with low-risk papillary thyroid carcinoma on active surveillance showed no altered tumor growth kinetics with GLP-1RA exposure 5
Clinical Application Algorithm
Step 1: Screen for absolute contraindications before prescribing any GLP-1 receptor agonist:
- Personal history of MTC? → Do not prescribe
- Family history of MTC? → Do not prescribe
- MEN-2A or MEN-2B diagnosis? → Do not prescribe
Step 2: If patient has differentiated thyroid cancer (papillary, follicular, Hürthle cell):
- Proceed with GLP-1 receptor agonist if otherwise indicated
- No special monitoring for thyroid cancer is required 3
- The FDA has stated that calcitonin monitoring is not necessary in patients taking GLP-1 receptor agonists 3
Step 3: Consider shorter-acting agents (exenatide twice daily or lixisenatide) if there is heightened concern, as these do not carry the same black box warnings 3
Critical Caveats
The rodent data does not translate to humans. Preclinical studies showed C-cell hyperplasia, adenomas, and medullary thyroid carcinomas in rodents treated with liraglutide and exenatide 3. However, human C-cells do not express GLP-1 receptors as rodent C-cells do, and placebo-controlled clinical trial data shows no evidence of increased calcitonin or C-cell neoplasia in humans 3.
Do not deny eligible patients the cardiometabolic benefits of GLP-1 receptor agonists based on unwarranted concerns about differentiated thyroid cancer. The evidence from randomized controlled trials indicates thyroid cancer occurrence is infrequent and there is no conclusive evidence of elevated risk 6. Recent data specifically in DTC patients supports safety 4, 5.
The contraindication is absolute only for MTC and MEN-2, not for other thyroid pathology including benign nodules, goiter, or differentiated thyroid cancers.